{"id":910146,"date":"2025-11-14T08:40:06","date_gmt":"2025-11-14T13:40:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe\/"},"modified":"2025-11-14T08:40:06","modified_gmt":"2025-11-14T13:40:06","slug":"nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe\/","title":{"rendered":"Nanox Partners with French Radiology Group Olympe Imagerie to Advance Clinical Validation in Europe"},"content":{"rendered":"
\n

\n Olympe Imagerie to deploy Nanox.ARC at Paris-area Hospital Priv\u00e9 Jacques Cartier MASSY for lung cancer screening applications<\/em>\n <\/p>\n

PETACH TIKVA, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD<\/a> (\u201cNanox\u201d or the \u201cCompany\u201d, Nasdaq: NNOX), an innovative medical imaging technology company, today announced a collaboration with Olympe Imagerie<\/a>, a Paris-based group of independent radiologists, to deploy the Nanox.ARC and expand its clinical research evidence generation program in France.<\/p>\n

The Nanox.ARC system is already on its way to France, marking an important progress as Nanox strengthens its European clinical and commercial presence.<\/p>\n

Under the collaboration, the Nanox.ARC<\/a> system will be deployed at Hospital Priv\u00e9 Jacques Cartier MASSY, one of the leading private hospital groups in the Paris metropolitan area, for clinical trials designed to further assess the value of the Nanox.ARC in supporting lung cancer detection, management, and screening.<\/p>\n

The Nanox.ARC is a multi-source digital tomosynthesis system that utilizes advanced 3D imaging technology to provide enhanced diagnostic capabilities at a lower cost than traditional systems. Following its CE Mark certification<\/a> in February 2025, the Nanox.ARC is cleared for commercialization across the European Union.<\/p>\n

Olympe Imagerie is an independent radiology group whose physicians provide imaging services at multiple centers across the Ile-de-France region in Antony, Massy and Dourdan. Collectively, these sites serve more than 400,000 outpatients, inpatients, and visitors each year.<\/p>\n

\u201cFrance is an important market for our European expansion strategy, and this collaboration advances our clinical validation efforts in a key geography,\u201d said Erez Meltzer, CEO and Acting Chairman of Nanox. \u201cBy partnering with Olympe Imagerie and Hospital Priv\u00e9 Jacques Cartier MASSY, we\u2019re positioning the Nanox.ARC to demonstrate its potential value in lung cancer screening, an important application where early detection can significantly improve patient outcomes.\u201d<\/p>\n

Romain Pommier, Associate Radiologist at Olympe Imagerie, said, \u201cWe are proud to collaborate with Nanox and to be among the first in Europe to evaluate this new and cutting-edge imaging system. helping us bring more inclusive and effective diagnostic solutions to patients. Lung cancer screening remains one of the most important applications in diagnostic radiology, and we\u2019re excited to evaluate how the Nanox.ARC\u2019s tomosynthesis capabilities can potentially enhance our ability to detect lung abnormalities earlier and more accurately. This collaboration is an important step in bringing advanced, accessible imaging technology to our patient population.\u201d<\/p>\n

\n About Nanox<\/strong>\n <\/p>\n

Nanox (NASDAQ: NNOX) is focused on driving the world\u2019s transition to preventive health care by bringing a full solution of affordable medical imaging technologies based on advanced AI and proprietary digital X-ray source.<\/p>\n

Nanox’s vision encompasses expanding the reach of Nanox technology both within and beyond hospital settings, providing a seamless end-to-end solution from scan to diagnosis, leveraging AI to enhance the efficiency of routine medical imaging technology and processes, in order to improve early detection and treatment and maintaining a clinically driven approach. The Nanox ecosystem includes Nanox.ARC \u2013 a multi-source digital tomosynthesis system that is cost-effective and user-friendly; Nanox.AI LTD \u2013 an AI-based suite of algorithms that augment the readings of routine CT imaging to highlight early signs often related to chronic diseases; Nanox.CLOUD \u2013 a cloud-based software platform that manages and stores data collected by Nanox devices, and provides users with tools for in-depth imaging analysis; Nanox.MARKETPLACE \u2013 a proprietary decentralized marketplace through Nanox\u2019s subsidiary, USARAD Holdings Inc., that provides remote access to radiology and cardiology experts, and a comprehensive teleradiology services platform. By improving early detection and treatment, Nanox aims to enhance better health outcomes worldwide. For more information, please visit www.nanox.vision<\/a><\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of the Company\u2019s research and development, manufacturing, and commercialization activities with respect to its X-ray source technology and the Nanox.ARC, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as \u201ccan,\u201d \u201cmight,\u201d \u201cbelieve,\u201d \u201cmay,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cshould,\u201d \u201cplan,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cexpect,\u201d \u201cpredict,\u201d \u201cpotential,\u201d or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management\u2019s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox\u2019s ability to complete development of the Nanox System; (ii) Nanox\u2019s ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox\u2019s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (iv) Nanox\u2019s ability to realize the anticipated benefits of the acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (v) Nanox\u2019s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vi) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (vii) Nanox\u2019s expectations regarding collaborations with third-parties and their potential benefits; (viii) Nanox\u2019s ability to conduct business globally; (ix) changes in global, political, economic, business, competitive, market and regulatory forces; (x) risks related to the current war between Israel and Hamas and any worsening of the situation in Israel; (xi) risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises, among other things; and (xii) potential litigation associated with our transactions.<\/p>\n

For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox\u2019s actual results to differ from those contained in the Forward-Looking Statements, see the section titled \u201cRisk Factors\u201d in Nanox\u2019s Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this press release. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company\u2019s expectations.<\/p>\n

\n Contacts<\/strong>\n <\/p>\n

\n Media Contact:<\/strong>
\n
Ben Shannon
ICR Healthcare
NanoxPR@icrinc.com<\/a><\/p>\n

\n Investor Contact<\/strong>:
Mike Cavanaugh
ICR Healthcare
mike.cavanaugh@icrhealthcare.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Olympe Imagerie to deploy Nanox.ARC at Paris-area Hospital Priv\u00e9 Jacques Cartier MASSY for lung cancer screening applications PETACH TIKVA, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD (\u201cNanox\u201d or the \u201cCompany\u201d, Nasdaq: NNOX), an innovative medical imaging technology company, today announced a collaboration with Olympe Imagerie, a Paris-based group of independent radiologists, to deploy the Nanox.ARC and expand its clinical research evidence generation program in France. The Nanox.ARC system is already on its way to France, marking an important progress as Nanox strengthens its European clinical and commercial presence. Under the collaboration, the Nanox.ARC system will be deployed at Hospital Priv\u00e9 Jacques Cartier MASSY, one of the leading private hospital groups in the Paris metropolitan area, for clinical … <\/p>\n

Continue reading “Nanox Partners with French Radiology Group Olympe Imagerie to Advance Clinical Validation in Europe”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-910146","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNanox Partners with French Radiology Group Olympe Imagerie to Advance Clinical Validation in Europe - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanox Partners with French Radiology Group Olympe Imagerie to Advance Clinical Validation in Europe - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Olympe Imagerie to deploy Nanox.ARC at Paris-area Hospital Priv\u00e9 Jacques Cartier MASSY for lung cancer screening applications PETACH TIKVA, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD (\u201cNanox\u201d or the \u201cCompany\u201d, Nasdaq: NNOX), an innovative medical imaging technology company, today announced a collaboration with Olympe Imagerie, a Paris-based group of independent radiologists, to deploy the Nanox.ARC and expand its clinical research evidence generation program in France. The Nanox.ARC system is already on its way to France, marking an important progress as Nanox strengthens its European clinical and commercial presence. Under the collaboration, the Nanox.ARC system will be deployed at Hospital Priv\u00e9 Jacques Cartier MASSY, one of the leading private hospital groups in the Paris metropolitan area, for clinical … Continue reading "Nanox Partners with French Radiology Group Olympe Imagerie to Advance Clinical Validation in Europe"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-14T13:40:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NTcyMSM3MjYzMjA1IzIxOTUyNTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nanox Partners with French Radiology Group Olympe Imagerie to Advance Clinical Validation in Europe\",\"datePublished\":\"2025-11-14T13:40:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe\\\/\"},\"wordCount\":1163,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3NTcyMSM3MjYzMjA1IzIxOTUyNTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe\\\/\",\"name\":\"Nanox Partners with French Radiology Group Olympe Imagerie to Advance Clinical Validation in Europe - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3NTcyMSM3MjYzMjA1IzIxOTUyNTY=\",\"datePublished\":\"2025-11-14T13:40:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3NTcyMSM3MjYzMjA1IzIxOTUyNTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3NTcyMSM3MjYzMjA1IzIxOTUyNTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanox Partners with French Radiology Group Olympe Imagerie to Advance Clinical Validation in Europe\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanox Partners with French Radiology Group Olympe Imagerie to Advance Clinical Validation in Europe - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe\/","og_locale":"en_US","og_type":"article","og_title":"Nanox Partners with French Radiology Group Olympe Imagerie to Advance Clinical Validation in Europe - Market Newsdesk","og_description":"Olympe Imagerie to deploy Nanox.ARC at Paris-area Hospital Priv\u00e9 Jacques Cartier MASSY for lung cancer screening applications PETACH TIKVA, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD (\u201cNanox\u201d or the \u201cCompany\u201d, Nasdaq: NNOX), an innovative medical imaging technology company, today announced a collaboration with Olympe Imagerie, a Paris-based group of independent radiologists, to deploy the Nanox.ARC and expand its clinical research evidence generation program in France. The Nanox.ARC system is already on its way to France, marking an important progress as Nanox strengthens its European clinical and commercial presence. Under the collaboration, the Nanox.ARC system will be deployed at Hospital Priv\u00e9 Jacques Cartier MASSY, one of the leading private hospital groups in the Paris metropolitan area, for clinical … Continue reading \"Nanox Partners with French Radiology Group Olympe Imagerie to Advance Clinical Validation in Europe\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-14T13:40:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NTcyMSM3MjYzMjA1IzIxOTUyNTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nanox Partners with French Radiology Group Olympe Imagerie to Advance Clinical Validation in Europe","datePublished":"2025-11-14T13:40:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe\/"},"wordCount":1163,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NTcyMSM3MjYzMjA1IzIxOTUyNTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe\/","name":"Nanox Partners with French Radiology Group Olympe Imagerie to Advance Clinical Validation in Europe - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NTcyMSM3MjYzMjA1IzIxOTUyNTY=","datePublished":"2025-11-14T13:40:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NTcyMSM3MjYzMjA1IzIxOTUyNTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NTcyMSM3MjYzMjA1IzIxOTUyNTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanox-partners-with-french-radiology-group-olympe-imagerie-to-advance-clinical-validation-in-europe\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nanox Partners with French Radiology Group Olympe Imagerie to Advance Clinical Validation in Europe"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/910146","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=910146"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/910146\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=910146"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=910146"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=910146"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}